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Small median tumor diameter at cure threshold (<20 mm)
among aggressive non-small cell lung cancers in male smokers
predicts both chest X-ray and CT screening outcomes
in a novel simulation framework
Deborah L. Goldwasser and Marek Kimmel
Department of Statistics, Rice University, Houston, TX
The effectiveness of population-wide lung cancer screening strategies depends on the underlying natural course of lung
cancer. We evaluate the expected stage distribution in the Mayo CT screening study under an existing simulation model of
non-small cell lung cancer (NSCLC) progression calibrated to the Mayo lung project (MLP). Within a likelihood framework, we
evaluate whether the probability of 5-year NSCLC survival conditional on tumor diameter at detection depends significantly on
screening detection modality, namely chest X-ray and computed tomography. We describe a novel simulation framework in
which tumor progression depends on cellular proliferation and mutation within a stem cell compartment of the tumor. We fit
this model to randomized trial data from the MLP and produce estimates of the median radiologic size at the cure threshold.
We examine the goodness of model fit with respect to radiologic tumor size and 5-year NSCLC survival among incident
cancers in both the MLP and Mayo CT studies. An existing model of NSCLC progression under-predicts the number of
advanced-stage incident NSCLCs among males in the Mayo CT study (p-value 5 0.004). The probability of 5-year NSCLC
survival conditional on tumor diameter depends significantly on detection modality (p-value 5 0.0312). In our new model,
selected solution sets having a median tumor diameter of 16.2–22.1 mm at cure threshold among aggressive NSCLCs predict
both MLP and Mayo CT outcomes. We conclude that the median lung tumor diameter at cure threshold among aggressive
NSCLCs in male smokers may be small (<20 mm).
Introduction
The ﬁrst randomized clinical trial (RCT) to demonstrate a
mortality beneﬁt associated with screening for lung cancer is
the national lung screening trial (NLST), reporting a 20.0%
reduction in lung cancer deaths among individuals screened
annually by computed tomography (CT) relative to individu-
als screened annually by chest X-ray.1 The prostate, lung,
colorectal, and ovarian (PLCO)2 study reported no mortality
beneﬁt associated with screening by chest X-ray after 13.5
years of follow-up, consistent with earlier ﬁndings from the
Mayo Lung Project (MLP).3
The NLST and PLCO results suggest that screening for
lung cancer by CT is likely to be effective in reducing lung
cancer mortality whereas screening by chest X-ray will not.
The NLST study found that CT detects lung nodules larger
than 4mm at a three-fold higher rate than chest-X-ray.1
However, the PLCO and MLP results likewise demonstrated
an increased rate of early-stage lung cancer detection attrib-
utable to chest X-ray screening, relative to usual care.2,4
Debate over the interpretation of chest X-ray screening
results persists.5–8 Estimates of the median size at which lung
cancers transition to advanced-stage of 40 mm suggest that a
mortality beneﬁt to chest X-ray screening should exist.9
The failure of chest X-ray screening studies to produce a
mortality beneﬁt has been widely attributed to overdiagnosis.6
However, data suggests that screen-detected lung cancers typ-
ically demonstrate rapid growth. A systematic literature
review of volume doubling times (VDTs) reports that the
mean proportions of VDTs greater than 400 days among
lung cancers detected by routine care, chest X-ray and CT
are 3, 8, and 27%, respectively.10 Average proportions of
tumors with VDTs less than 100 days among lung cancers
detected by routine care, chest X-ray and CT are 44, 39,
and 29%, respectively.10 The proportion of rapidly-growing
lung cancers may in fact be higher. Inclusion of baseline can-
cers (inﬂuenced by length bias) and exclusion of single
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measurement cancers may bias VDT estimates toward slower
growth.11 In the Mayo CT, detection of baseline cancers was
two-fold higher in females than males, suggesting that the
proportion of rapid-growing cancers may be higher in men
than women.11 Furthermore, nonsolid or part-solid nodules
may appear slow-growing but in fact become denser and
increase in cell volume.12
The effectiveness of lung cancer screening depends on the
underlying natural course of lung cancer. In this study, we
characterize a model of lung cancer progression having two key
features, namely VDT and the radiologic size at cure threshold,
the size at which a lung cancer is no longer curable. When lung
cancer is detected at a localized stage, it can be successfully
treated by surgical resection followed by chemotherapy.
We ﬁt a model of lung cancer natural course to random-
ized trial data from the MLP. MLP data distinguishes
between lung cancers detected during the study and lung
cancers detected at the time of the prevalence screen. Preva-
lent cancers are subject to length bias since slow-growing or
indolent cancers are likely to be over-represented in a popu-
lation at a given point in time. In contrast, incident cancers
arise during the screening study, following a negative preva-
lence screen. In the context of the MLP, incident cancers
from the usual-care arm and the chest X-ray arm provide
nearly unbiased random samples with respect to lung cancer
growth and progression. On average, incident cancers in the
usual-care arm are expected to reﬂect a later progression
point in the natural course of lung cancer.
Evidence from the surveillance, epidemiology, and end
results (SEER) cancer registry suggests that the smaller the
tumor size, the more likely it is that a lung cancer has not
spread to lymph nodes or metastasized. In a study of 84,152
non-small cell lung cancer (NSCLC) cases documented in
SEER, among tumors less than 15 mm in diameter, the pro-
portion of Stage I cancers was 54% (N ¼7,327) whereas
among tumors greater than 45 mm in diameter, the propor-
tion of Stage I cancers was 15% (N ¼ 31,623), with interme-
diate size strata reﬂecting a declining proportion of Stage I
lung cancers.13 SEER and hospital registry data must be
interpreted with care. These data reﬂect not only the underly-
ing natural course of lung cancer but also the size-dependent
probability of lung cancer detection.
Stage-shift refers to a shift in the stage distribution of
lung cancers between two distinct populations. The presence
of a stage-shift among small T1 lung tumors (<3 cm) is con-
sidered especially relevant to screening because screening has
the ability to detect small lung cancers. In the SEER study,
among tumors between 16 and 25 mm in diameter, 46% (N
¼ 15,853) were Stage I, signiﬁcantly smaller than the 54%
proportion of Stage I cancers less than 15 mm in diameter.13
Some studies of hospital registry data have conﬁrmed this
result14,15 whereas others have failed to document this stage-
shift.16 Hospital registry data-sets may be up to two orders of
magnitude smaller than SEER and biased toward surgical
cases.17 A stage-shift between chest X-ray detected and CT-
detected incident cancers is expected because chest X-ray-
detected cancers are larger, attributable to the lower sensitiv-
ity of chest X-ray.
Population-based models of lung cancer natural course
have been previously developed to aid the interpretation of
lung screening outcomes.18,19 We introduce a novel estima-
tion framework and speciﬁcally evaluate the consistency of
estimates of radiologic size at cure threshold with both
reported chest X-ray and CT outcomes.
Data, Methods, and Models
Mayo CT
The Mayo CT study was a prospective cohort study which
began in 1999 and recruited 1,520 individuals (788 male, 732
female) greater than 50 years of age with a smoking history
of more than 20 pack-years. Study participants received a
baseline screen followed by four additional annual-repeat
screens. We adopt the classiﬁcation that prevalent lung can-
cers were visible at baseline, but possibly ﬁrst detected during
the study period. Incident cancers ﬁrst became visible during
the annual-repeat screening period. Interval cancers arose
between annual-repeat screens. We obtained access to Mayo
CT radiologic and pathologic records through participation
in CISNET (www.cisnet.cancer.gov). Up to six nodules were
reported for each study participant at the annual-repeat
radiologic screen each year. We identiﬁed the largest among
the reported nodules consistent with surgical location and
timing of pathologic staging in order to reﬂect the radiologic
size at detection among conﬁrmed lung cancers. A total of 66
lung cancers were conﬁrmed during the Mayo CT study.
MLP
The MLP was a RCT initiated in 1971 and completed on
July 1, 1983 which recruited 10,933 male smokers over the
age of 45 years. Of the original recruitment pool, 9,211 were
accepted for randomization into a screening arm (N ¼ 4,618)
and a control arm (N ¼ 4,593), based on a negative preva-
lence screen and the satisfaction of other entry criteria. MLP
participants must have had an estimated life expectancy of
ﬁve years or more, sufﬁcient respiratory reserve to undergo
pulmonary resection, no prior history of cancer of the lung
or respiratory tract and no presentation of symptoms of lung
cancer.4 In the ﬁrst seven trial years, there were 91 preva-
lence lung cancers, 151 incidence lung cancers (115 NSCLC)
diagnosed in the screening arm and 120 incidence lung can-
cers (86 NSCLC) diagnosed in the control arm. We obtained
the original radiology and pathology data reported during the
MLP as well as extended mortality follow-up data.
Stage shift analysis
To simulate the age at lung cancer onset in the Mayo CT
study, we adopt the two-stage clonal expansion (TSCE)
model calibrated to the Nurses’ Health Study and the Health
Professionals Follow-Up Study.20 The TSCE model incorpo-
rates gender and smoking-dependent parameter estimates
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and simulates the time of the appearance of the ﬁrst malig-
nant cell. After the appearance of the ﬁrst malignant cell, we
assume a ﬁxed lag time of 6 months before the cancer
becomes visible by CT. Given a model of tumor progression
ﬁt to the MLP, the lung cancer subsequently progresses
through early and advanced stages governed by two inde-
pendent exponential distributions.5 Age and smoking-de-
pendent other-cause mortality hazard functions are provided
as a CISNET resource.
We simulate 10,000 iterations of the Mayo CT study and
obtain expected counts of early and advanced-stage prevalent
and incident NSCLCs (Table 1) among male participants.
Higher sensitivity of CT relative to chest X-ray is expected to
produce a stage-shift. We compute a test statistic based on
the squared difference between expected and observed can-
cers in each of the four categories.
MSE ¼
X4
i¼1
ðExpectedi  ObservediÞ2
Expectedi
The reported p-value is deﬁned as the frequency of observing
a MSE value as large or larger as the observed MSE statistic
among the N ¼ 10,000 simulations.
Probability of NSCLC death as a function of size at
detection
For the 115 incident NSCLCs conﬁrmed in the screened
arm of the MLP, we collected data on radiologic tumor
size and 5-year survival. Eleven NSCLCs were sputum-
detected only, having unknown radiologic size and were
omitted from the analysis. Among the 104 remaining
NSCLCs, there were 52 lung cancer deaths, 11 other-cause
deaths (9 Stage I, 2 Stage III) and four study-related deaths
(3 Stage I, 1 Stage III) within 5 years of NSCLC detection.
The remaining 37 individuals were alive after 5 years of
NSCLC detection. For censored MLP cases, we impute
Stage I cases as alive at ﬁve years and Stage IIþ cases as
resulting in lung cancer death. Among NSCLCs with
reported radiologic sizes of either (i) not measurable but
greater than 3 cm or (ii) not measurable but less than 3
cm, we impute the size as the median size among inci-
dence NSCLCs in the similar size and survival category.
Among the 14 interval and incidence NSCLCs in males
detected in the Mayo CT, there were eight lung cancer
deaths and six individuals were alive at the end of the fol-
low-up period. The median follow-up time after initial
detection for survivors was 4.0 years. In all cases, we sum-
marize the tumor diameter as the average of the reported
long and short axes. A comparison of the reported tumor
diameter information between the Mayo CT and MLP is
given in Table 2.
We assume the conditional cumulative density function of
LC death as a function of tumor diameter at detection fol-
lows a gamma distribution with shape and scale parameters,
alpha (a) and gamma (c), respectively. Under the minimal
assumption that tumors increase uniformly in size, we deﬁne
a likelihood function as follows:
For detected NSCLCs with diameter s0, resulting in no LC
death:
Pr ½LC Death ¼ 0 jDetection ¼ s0 ¼ Pr ½X > s0 ja; c
For detected NSCLCs with diameter s1, resulting in a LC
death:
Pr ½LC Death ¼ 1 jDetection ¼ s1 ¼ Pr ½X < s1 ja; c
Table 1. Comparison of observed and expected non-small cell lung cancers in a simulation of the Mayo CT Study (males only)
Simulated (CT Sensitivity ¼ 0.9) Simulated (CT Sensitivity ¼ 0.8) Observed
Prevalence (early-stage) 10.1 9.5 8
Prevalence (advanced-stage) 6.6 6.9 3
Incidence/Interval (early-stage) 11.2 10.9 7
Incidence/interval (advanced-stage) 1.9 2.1 7
Totals 29.9 29.4 25
Table 2. Radiologic sizes of non-small cell lung cancer incident and interval cancers in the Mayo Lung Project and the Mayo CT study (males
only)
Mayo Lung Project N (Known Size/Total) Median Diameter (mm) Mean Diameter (mm)
Screened Arm Alive after 5 Years 43/49 25 26.35
LC death within 5 years 43/55 35 36.44
Control Arm Alive after 5 years 18/19 36.5 32.17
LC death within 5 years 50/67 43.5 42.25
Mayo CT No LC death 6/6 8.75 8.83
LC death 7/8 12.5 15.07
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Asymptotic properties of maximum likelihood statistical
methods are well deﬁned.21 Maximum likelihood estimates
(MLEs) for the shape parameter, a, and the scale parameter,
c, are obtained under a bounded variance constraint: variance
is assumed bounded by the sample variance of radiologic
sizes at detection in the pooled group. We estimate the MLE
vector (x) for the pooled sample of Mayo CT and MLP lung
cancers as well as for each individual data-set separately.
Based on x and the resulting Hessian matrix, R1, we report
a 95% conﬁdence interval for the median of the distribution
for each data-set independently. The 95% conﬁdence interval
for the median is computed on parameter values of x falling
within the 95% conﬁdence ellipse given by: x [ (x 
l)
0
R1(x  l) < v22;0:95. We conduct a likelihood ratio test to
examine the strength of the evidence that a unique parameter
vector is consistent with data from both the MLP and Mayo
CT. We compute:
 2 ln Lða^; c^jsÞMLPLða^; c^jsÞMayoCT
Lða^; c^jsÞpooled
where s is the vector of detection sizes and obtain the result-
ing p-value based on a chi-squared distribution having two
degrees of freedom. We compute the probability that a 10-
mm NSCLC detected by chest X-ray and CT will result in a
lung cancer death with the associated 95% conﬁdence
interval.
Multi-type branching process model
We describe a multi-type branching process model in which
cancer arises from a single stem-like malignant progenitor
cell. Upon cell division, this progenitor cell gives rise to two
identical stem-like cells with probability f and gives rise to
one stem-like progenitor cell and one terminally differenti-
ated cell with probability 1-f. Tumor growth occurs as the
result of the accumulation of cells from multiple cell divi-
sions. We assume a pure-birth process in which terminally
differentiated cells contribute to the overall size of the tu-
mor but, unlike stem-like progenitor cells, do not undergo
further cell division events. The accumulation of n key
mutations in a stem-like progenitor cell results in the de-
velopment of an incurable tumor, ultimately resulting in a
lung cancer death. We deﬁne the tumor diameter at which
n mutations have accumulated as the cure threshold. The
probability of any of the n key mutations occurring at a
cell division step equals l.
We assume the average volume occupied by a single cell
of clonal origin is 50 lm. Conversion between cell number
and tumor diameter is based on the volume equation V ¼ 4/
3 pr3. We allow the range of parameter values to encompass
a spectrum of doubling times ranging from 20 to 300 days
and a stem cell fraction of up to 5%. The median size at the
cure threshold over this parameter range for f and l is repre-
sented in Table 3.
We collect data on tumor size, survival, and screen history
for incident NSCLCs arising during the MLP and Mayo CT
studies. We simulate a joint uniform vector [U1, U2] repre-
senting VDTs [range: 20:300] and median size at cure thresh-
old [range: 5:100]. We determine the values of f and l corre-
sponding to [U1, U2] by the relationship U1 ¼ ln(2)/f and by
inverse mapping of an expanded Table 3. We generate the
resulting tumor trajectory and retain the values of f and l,
contingent on the following:
1. For NSCLCs resulting in no lung cancer death (cura-
ble), the simulated size at cure threshold is larger than
the size at detection.
2. For NSCLCs resulting in a lung cancer death (incura-
ble), the simulated size at cure threshold is smaller
than the size at detection.
3. Given a screen history before detection (f, l) if and
only if U > 1  eadb for each tumor size at the timing
of each of p prior screens, where U is a uniform ran-
dom variable on [0,1]. We assume a Weibull screen
detection probability function having a 50% probability
of detection for a 30-mm nodule.
We assume a NSCLC is visible at the earliest screen
among repeat screens within a window of 75 days directly
before lung cancer diagnosis. Chest X-ray screens may be
performed after nodule detection but before lung cancer di-
agnosis as part of the diagnostic work-up. For every
Table 3. Median tumor diameter (mm) at cure threshold as a function of doubling time (Ln (2)/f)) and Log10 (mutation rate (l))
Log10 (mutation rate (l))
Doubling Time (Days) 5.15 4.95 4.75 4.55 4.35 4.15 3.95 3.75 3.55 3.35
40 100.3 100.3 100.2 100.2 77.4 46.5 28.3 16.9 10.2 6.5
80 100.1 100.1 100.1 71.5 44.7 26.8 16.6 10.1 6.5 5.0
120 100.1 100.1 91.0 53.8 30.2 19.8 12.7 7.8 5.1 5.0
160 100.1 100.0 73.2 44.2 26.9 16.4 10.1 6.7 5.0 5.0
200 100.0 100.0 60.5 37.8 21.3 13.6 8.8 5.7 5.0 5.0
240 100.0 92.4 53.6 32.2 20.2 12.5 7.9 5.0 5.0 5.0
280 100.0 80.5 47.0 29.2 18.3 11.3 7.0 5.0 5.0 5.0
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screened arm NSCLC having known tumor diameter at
detection, we continue replacement sampling until 1,000
values of f and l are generated.
We estimate size-dependent clinical detection in the control
arm using Kaplan-Meier (KM) estimation, separately for curable
and incurable NSCLCs. We estimate upper and lower KM
bounds, based on minimum and maximum numbers of
NSCLCs at risk of detection for each size, respectively. The true
number of NSCLCs at risk of curable or incurable detection for
each tumor size is unknown. For example, it is not known
whether a 40-mm incurable NSCLC had been incurable at 20
mm. We identify a set of Weibull distribution functions that fall
within the upper and lower KM bounds to represent the size-de-
pendent detection probability of control arm cancers (Fig. 1).
For each parameter pair (f, l), we compute the probability
that a NSCLC is detected in the control arm. We assume a
uniform distribution governing the onset of detectable
NSCLC within the screening window and specify the Weibull
probability functions governing NSCLC detection in the con-
trol arm. We consider only trajectories of (f, l) for which the
NSCLC fails to be detected at the prevalence screen but
would be screen-detectable by a single screen at the end of
the follow-up period. The precision of the probability esti-
mates for each parameter pair (f, l) is based on 10,000 simu-
lated trajectories. Based on the estimation principle of
method of moments (MOM), we deﬁne a solution as a set of
parameter values (fi, li) satisfying:
RNi¼1p1ðfi; liÞ ¼ C1 and RNi¼1p2ðfi;liÞ ¼ C2
where p1 ¼ probability of curable NSCLC detection, p2 ¼
probability of incurable NSCLC detection, N ¼ the number of
screened arm-detected NSCLCs, C1 ¼ the number of curable
control arm NSCLCs, and C2 ¼ the number of incurable con-
trol arm NSCLCs. We opt for a MOM estimation approach to
eliminate model constraints associated with maximum likeli-
hood estimation. To obtain a MOM solution to the parameter
space, we ﬁrst draw a random set of N screened-arm NSCLCs.
If a selected screened-arm NSCLC has missing tumor size in-
formation, we select a set of parameter values consistent with
the NSCLC having the identical survival status but known size
information. We allow C1 and C2 to vary according to a mul-
tinomial distribution with proportions of curable, incurable
and missed NSCLCs equal to C1/N, C2/N, and (N-C1-C2)/N,
respectively. We search the parameter space to obtain up to
1,000 solutions for each of the 20 detection scenarios.
For each of the 20 detection scenarios, we report the me-
dian VDTs and median tumor diameters at cure threshold
among all screened-arm detected NSCLCs and for the subset
of incurable NSCLCs detected in the control arm, averaged
over 100 MOM-calibrated models. We also report the aver-
age median tumor diameters at detection for curable and in-
curable NSCLCs and the proportion of curable NSCLCs in
the control arm of the MLP (Table 4). We select four repre-
sentative MOM-calibrated models from different detection
scenarios. To simulate screened-arm outcomes in the MLP,
we assume a screen detection function having 99% probabil-
ity of detection for a 30-mm nodule with 75% of NSCLCs in
a detectable location of the chest. We simulate both arms of
the MLP and the single arm of the Mayo CT study and
report the simulation outcomes reﬂecting goodness of each
model ﬁt (Table 5).
Results
In the Mayo CT, the proportion of lung cancer deaths
among incident NSCLCs (8/14) in males was similar to the
proportion of lung cancer deaths among incident NSCLCs
detected in the MLP (55/104). Our existing simulation
model predicts a stage-shift among incident NSCLCs rela-
tive to the MLP, resulting in a MSE p-value of either
Figure 1. Cumulative density functions (cdfs) representing the
probability of detection as a function of tumor diameter for (a)
curable lung cancers and (b) incurable lung cancers in the absence
of screening. (a) Kaplan-Meier upper and lower bounds and
intermediate Weibull (a,b) cdfs representing the probability of
detection of curable cancers in the absence of screening (1). (i)
Upper and lower Kaplan-Meier bounds (*), Weibull (9E-05,2.5) (D),
Weibull (6E-05,2.5) (x), Weibull (4E-05,2.5) (o), Weibull (3E-05,2.5)
(---), Weibull (2E-05,2.5) (þ). b) Kaplan-Meier upper and lower
bounds and intermediate Weibull (a,b) cdfs representing the
probability of detection of incurable cancers in the absence of
screening (2). (ii) Upper and lower Kaplan-Meier bounds (*), Weibull
(2.5E-02,2.5) (*), Weibull (2.5E-04,2.5) (x), Weibull (9E-05,2.5) (þ),
Weibull (6E-05,2.5) (o). [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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0.0026 or 0.0077, given CT detection sensitivity of either
90 or 80%, respectively.
Among the 104 incident NSCLCs detected in the
screened-arm of the MLP, there were 41 squamous-cell lung
cancers, 39 adenocarcinomas, 23 large-cell lung cancers, and
one cancer of another histologic sub-type. Association
between 5-year NSCLC survival and histologic sub-type was
not detected by chi-square association analysis (p-value¼
0.6529). ANOVA analysis failed to detect a difference among
the mean NSCLC tumor diameters at detection for any histo-
logic subtype for either curable (p-value ¼ 0.6503) or incura-
ble NSCLCs (p-value ¼ 0.7893). Among the 14 incident
NSCLCs detected in the Mayo CT, there were seven squa-
mous-cell lung cancers, two adenocarcinomas, and ﬁve other
histologic sub-types. With the exception of one incurable
Stage IIB squamous-cell lung cancer with a tumor diameter
of 33 mm, all incident NSCLCs in the Mayo CT study
among males had a tumor diameter less than 20 mm.
Based on a likelihood ratio test, the probability of 5-year
NSCLC survival as a function of tumor diameter differs sig-
niﬁcantly by detection modality (p ¼ 0.0312). In the MLP,
the estimated tumor diameter at detection at which 50% of
NSCLCs are curable is 27.61 mm [95% CI: (17.7, 33.3)]
whereas in the Mayo CT, the estimated tumor diameter at
detection for which 50% of NSCLCs are curable is 10.14 mm
[95% CI: (0.13, 13.8)]. In the MLP, the estimated probability
of lung cancer death given a 10 mm detected NSCLC is
7.1%[95% CI: (3.4%,27.8%)] whereas in the Mayo CT, the
estimated probability of lung cancer death given a 10 mm
detected NSCLC is 48.5% [95% CI: (17.8%,99%)].
We successfully identiﬁed parameter sets over all but two
of the 20 detection scenarios satisfying the MOM estimation
criteria. The median tumor diameter at cure threshold aver-
aged over 100 MOM parameter sets varies by detection sce-
nario and ranges from 14.4 to 31.6 mm. In a simulation of
the MLP, the close approximation to the observed proportion
of 22% curable NSCLCs among control-arm cancers reﬂects
the MOM estimation criteria. The estimates of median tumor
diameter at cure threshold among the subset of incurable
detected control-arm NSCLCs in the MLP varied by detec-
tion scenario and ranged in our simulations from 11.3 mm
to 22.1 mm.
We incorporated four speciﬁc MOM parameter sets into
the tumor progression component of the simulation models
of the MLP and Mayo CT studies (Table 5). For each of the
simulations, the number of curable and incurable incident
NSCLCs detected in the Mayo CT and their respective tumor
diameters at detection lie within or nearly within the 90%
range of simulated outcomes. In the MLP simulation, the
total number of NSCLCs in the control arm is closely pre-
dicted, as is the observed proportion of incurable lung can-
cers (22%). In all simulations excepting detection scenario
two, the median tumor diameters at detection lie within or
nearly within the 90% range of simulated outcomes for con-
trol-arm NSCLCs. With respect to screened-arm MLP out-
comes, an exception to the goodness of ﬁt is the under-esti-
mation of the median tumor diameters at detection of
curable NSCLCs.
Discussion
An existing simulation model of lung cancer natural course
predicts a stage-shift among incident lung cancers in the
Mayo CT relative to the MLP. Simulations proved incom-
patible with the observed Mayo CT incident data despite
the smaller sizes of Mayo CT incident lung cancers. These
results appear to contradict SEER data demonstrating a
decreasing proportion of Stage I lung cancers with increas-
ing tumor diameter. However, in both the Mayo CT and
MLP individually, early-stage lung cancers were smaller
than advanced-stage cancers, consistent with SEER trends.
Between data-sets, advanced-stage cancers in the Mayo CT
were smaller than early-stage cancers detected in the MLP.
CT is able to detect lung cancers at small sizes not previ-
ously seen by usual care nor by chest X-ray. An advanced,
incurable lung cancer which may have been detected by usual
care at a size of 45 mm may now be detected by CT having
a tumor diameter of 15 mm. This lung cancer, not previously
observed at 15 mm, may still be an advanced, incurable lung
cancer. We ﬁnd that detection modality is a signiﬁcant factor
in the prediction of 5-year lung cancer survival as a function
of tumor size. The broad implication of this ﬁnding is that
small tumors detected by CT may be more aggressive than
small lung cancers seen previously.
Our estimates of the median tumor diameter at cure
threshold are substantially smaller than median diameters of
advanced-stage lung tumors in SEER. It has been noted that
bias in SEER in the form of underrepresentation of small,
asymptomatic early-stage lung cancers and under-reported
size information among large, unresected advanced-stage
lung cancers is likely to strengthen the reported relationship
between tumor size and stage.13 However, under-representa-
tion in SEER of small, asymptomatic advanced-stage cancers
could weaken the reported relationship between tumor size
and stage. Data from the lung screening study, the NLST
pilot study, demonstrated a two-fold higher detection rate for
advanced-stage lung cancers in the CT screened arm com-
pared to the chest X-ray screened arm, thereby challenging
the assumption that advanced-stage cancers remain asymp-
tomatic only for a negligible period of time.22
Our cure threshold models are ﬁt to data from the MLP,
for which lung cancers were detected and treated between
1971 and 1983. If 5-year survival trends have signiﬁcantly
improved over the past 30 years, then the cure threshold
models we produce may be anachronistic when applied to
today’s screening methods. Five-year lung cancer survival
remains poor. According to a study of SEER survival trends,
the 5-year NSCLC survival among males was 13.4% over the
period 1978 to 1980, improving to 15.4% between 1999 to
2005,23 a modest 2% improvement in NSCLC survival over a
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period of 25 years. Furthermore, the PLCO screening study
conﬁrms the nearly 30-year old MLP results reporting no
mortality beneﬁt associated with early detection by chest
X-ray.2
The NLST has been called the ‘‘best umpire in town,’’ in
determining whether a lung cancer mortality reduction at-
tributable to CT exists.24 However, variation in CT screening
outcomes across studies is notable. The frequency of Stage I
annual-repeat lung cancers was 48.6% (17/35) in the Mayo
CT study, 46.8% (15/32) in the DANTE CT screening study,
similar to the 48.6% (68/140) Stage I annual-repeat cancers
observed in the ﬁrst 7 years of the MLP, when sputum-
detected cases are excluded.4,25,26 The New York ELCAP
reported that among 48 lung cancers detected in annual
repeat screens and not visible at baseline, 79.2% (38/48) were
classiﬁed as N0M0.27 In the Dutch NELSON study, 73.7%
(42/57) cancerous nodules detected in the second round of
screening were classiﬁed as pathological stage I.28
Variation in CT mortality outcomes presupposes the
observed variation in stage distribution among CT-detected
incident cancers. In a matched cohort analysis, estimates of
mortality reduction in the New York component of the I-
ELCAP screening study are 36% and 64% when data are
compared to the CPS-II and CARET studies, respectively.29
A distinguishing feature of the I-ELCAP protocol is the
aggressive management of annual-repeat lung cancers: biopsy
by ﬁne-needle aspiration is recommended if growth is seen
for a new non-calciﬁed nodule larger than 5 mm, as mea-
sured at a repeat CT scan after one month of detection.30 If
a large proportion of aggressive NSCLCs have a cure thresh-
old below 20 mm, a high sensitivity to variation among CT
screening protocols is expected.
It has been suggested that increasing the size threshold for
biopsy will reduce the false positive rate among CT-detected
lung cancers and reduce overdiagnosis.31 The effect of
increasing the size threshold on the detection of true positive
cases at an early-stage is presumed small, but this depends
on a comprehensive understanding of lung cancer natural
course. If raising the size threshold for biopsy leads to many
NSCLCs being missed at a curable size, then the ratio of false
positive cases to curable true positive cases may, in fact,
increase.
In conclusion, the NLST study has demonstrated that
lung cancer mortality can be reduced by CT screening. Ques-
tions remain concerning the optimal implementation of early
detection strategies.
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